Specifically, Bean et al. evaluated 701 bone or soft tissue sarcomas by immunohistochemistry analysis for ASS1 expression and found that most primary bone tumors (87.2%, 34/39) and soft tissue tumors (86.4%, 572/662) had low ASS1 expression. The gene discussed is ASS1; the disease is bone neoplasm.